Merck-KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Disease Progression or Death Versus Chemotherapy With or Without Bevacizumab in Certain Patients With Platinum-Resistant Recurrent Ovarian Cancer

KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Disease Progression or Death Versus Chemotherapy With or Without Bevacizumab in Certain Patients With Platinum-Resistant Recurrent Ovarian Cancer

默克(US:MRK) Businesswire·2025-10-18 22:35

临床试验数据公布 - 公司首次公布关键三期KEYNOTE-B96试验结果 [1] - 该试验评估KEYTRUDA联合化疗用于治疗铂类耐药复发性卵巢癌患者 [1] - 这些最新突破性数据将在学术会议上进行展示 [1]